NCT00795145View on ClinicalTrials.gov

A Study To Assess The Effect Of Linezolid On QTc Interval

PHASE1CompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Bacterial Infections

Interventions

DRUG

Placebo

Intravenous, Placebo control for blinding, Normal Saline, Single dose

DRUG

Linezolid 900 mg

Intravenous, 900 mg linezolid, single dose

DRUG

Linezolid 1200 mg

Intravenous, 1200 mg linezolid, single dose

DRUG

Placebo

Intravenous, Placebo control for blinding, Normal Saline, Single dose

DRUG

Linezolid 600 mg

Intravenous, 600 mg linezolid, single dose

DRUG

Linezolid 1200 mg

Intravenous, 1200 mg linezolid, single dose

DRUG

Moxifloxacin 400 mg

Oral, 400 mg moxifloxacin, single dose

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT00795145 - A Study To Assess The Effect Of Linezolid On QTc Interval | Biotech Hunter | Biotech Hunter